These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25165007)

  • 21. Novel diaryl ether derivatives as InhA inhibitors: Design, synthesis and antimycobacterial activity.
    Abdelaziz OA; Othman DIA; Abdel-Aziz MM; Badr SMI; Eisa HM
    Bioorg Chem; 2022 Dec; 129():106125. PubMed ID: 36126606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis.
    Sullivan TJ; Truglio JJ; Boyne ME; Novichenok P; Zhang X; Stratton CF; Li HJ; Kaur T; Amin A; Johnson F; Slayden RA; Kisker C; Tonge PJ
    ACS Chem Biol; 2006 Feb; 1(1):43-53. PubMed ID: 17163639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 4-Aryl-1,4-Dihydropyridines as Potential Enoyl-Acyl Carrier Protein Reductase Inhibitors: Antitubercular Activity and Molecular Docking Study.
    Venugopala KN; Deb PK; Pillay M; Chopra D; Chandrashekharappa S; Morsy MA; Aldhubiab BE; Attimarad M; Nair AB; Sreeharsha N; Kandeel M; Venugopala R; Mohanlall V
    Curr Top Med Chem; 2021; 21(4):295-306. PubMed ID: 33138763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data.
    Kuo MR; Morbidoni HR; Alland D; Sneddon SF; Gourlie BB; Staveski MM; Leonard M; Gregory JS; Janjigian AD; Yee C; Musser JM; Kreiswirth B; Iwamoto H; Perozzo R; Jacobs WR; Sacchettini JC; Fidock DA
    J Biol Chem; 2003 Jun; 278(23):20851-9. PubMed ID: 12606558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis.
    Luckner SR; Liu N; am Ende CW; Tonge PJ; Kisker C
    J Biol Chem; 2010 May; 285(19):14330-7. PubMed ID: 20200152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-tubercular activity and molecular docking studies of indolizine derivatives targeting mycobacterial InhA enzyme.
    Venugopala KN; Chandrashekharappa S; Deb PK; Tratrat C; Pillay M; Chopra D; Al-Shar'i NA; Hourani W; Dahabiyeh LA; Borah P; Nagdeve RD; Nayak SK; Padmashali B; Morsy MA; Aldhubiab BE; Attimarad M; Nair AB; Sreeharsha N; Haroun M; Shashikanth S; Mohanlall V; Mailavaram R
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1472-1487. PubMed ID: 34210233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.
    Perryman AL; Yu W; Wang X; Ekins S; Forli S; Li SG; Freundlich JS; Tonge PJ; Olson AJ
    J Chem Inf Model; 2015 Mar; 55(3):645-59. PubMed ID: 25636146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis.
    Inturi B; Pujar GV; Purohit MN
    Arch Pharm (Weinheim); 2016 Nov; 349(11):817-826. PubMed ID: 27775177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pyrrolidinone and pyrrolidine derivatives: Evaluation as inhibitors of InhA and Mycobacterium tuberculosis.
    Matviiuk T; Madacki J; Mori G; Orena BS; Menendez C; Kysil A; André-Barrès C; Rodriguez F; Korduláková J; Mallet-Ladeira S; Voitenko Z; Pasca MR; Lherbet C; Baltas M
    Eur J Med Chem; 2016 Nov; 123():462-475. PubMed ID: 27490025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of New and Potent InhA Inhibitors as Antituberculosis Agents: Structure-Based Virtual Screening Validated by Biological Assays and X-ray Crystallography.
    Kamsri P; Hanwarinroj C; Phusi N; Pornprom T; Chayajarus K; Punkvang A; Suttipanta N; Srimanote P; Suttisintong K; Songsiriritthigul C; Saparpakorn P; Hannongbua S; Rattanabunyong S; Seetaha S; Choowongkomon K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Chen Z; Zhu W; Blood RA; Takebayashi Y; Hinchliffe P; Mulholland AJ; Spencer J; Pungpo P
    J Chem Inf Model; 2020 Jan; 60(1):226-234. PubMed ID: 31820972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tryptanthrin Analogues as Inhibitors of Enoyl-acyl Carrier Protein Reductase: Activity against Mycobacterium tuberculosis, Toxicity, Modeling of Enzyme Binding.
    Duca G; Pogrebnoi S; Boldescu V; Aksakal F; Uncu A; Valica V; Uncu L; Negres S; Nicolescu F; Macaev F
    Curr Top Med Chem; 2019; 19(8):609-619. PubMed ID: 30834838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-based design of a novel class of potent inhibitors of InhA, the enoyl acyl carrier protein reductase from Mycobacterium tuberculosis: a computer modelling approach.
    Subba Rao G; Vijayakrishnan R; Kumar M
    Chem Biol Drug Des; 2008 Nov; 72(5):444-9. PubMed ID: 19012578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of 9H-fluorenone based 1,2,3-triazole analogues as Mycobacterium tuberculosis InhA inhibitors.
    Suresh A; Srinivasarao S; Agnieszka N; Ewa AK; Alvala M; Lherbet C; Chandra Sekhar KVG
    Chem Biol Drug Des; 2018 Jun; 91(6):1078-1086. PubMed ID: 29063733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery and development of novel rhodanine derivatives targeting enoyl-acyl carrier protein reductase.
    Xu JF; Wang TT; Yuan Q; Duan YT; Xu YJ; Lv PC; Wang XM; Yang YS; Zhu HL
    Bioorg Med Chem; 2019 Apr; 27(8):1509-1516. PubMed ID: 30846404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In Vitro Antimycobacterial Activity and Physicochemical Characterization of Diaryl Ether Triclosan Analogues as Potential InhA Reductase Inhibitors.
    Ibrahim TS; Taher ES; Samir E; M Malebari A; Khayyat AN; Mohamed MFA; Bokhtia RM; AlAwadh MA; Seliem IA; Asfour HZ; Alhakamy NA; Panda SS; Al-Mahmoudy AMM
    Molecules; 2020 Jul; 25(14):. PubMed ID: 32650556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors: A combined in-silico and in-vitro analysis.
    Lone MY; Athar M; Gupta VK; Jha PC
    J Mol Graph Model; 2017 Sep; 76():172-180. PubMed ID: 28734205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Machine learning assisted methods for the identification of low toxicity inhibitors of Enoyl-Acyl Carrier Protein Reductase (InhA).
    Chikhale RV; Abdelghani HTM; Deka H; Pawar AD; Patil PC; Bhowmick S
    Comput Biol Chem; 2024 Jun; 110():108034. PubMed ID: 38430612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of novel InhA reductase inhibitors: application of pharmacophore- and shape-based screening approach.
    Kumar UC; Bvs SK; Mahmood S; D S; Kumar-Sahu P; Pulakanam S; Ballell L; Alvarez-Gomez D; Malik S; Jarp S
    Future Med Chem; 2013 Mar; 5(3):249-59. PubMed ID: 23464516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Hybrid 1,2,4- and 1,2,3-Triazoles Targeting Mycobacterium Tuberculosis Enoyl Acyl Carrier Protein Reductase (InhA): Design, Synthesis, and Molecular Docking.
    El Sawy MA; Elshatanofy MM; El Kilany Y; Kandeel K; Elwakil BH; Hagar M; Aouad MR; Albelwi FF; Rezki N; Jaremko M; El Ashry ESH
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacophore mapping, molecular docking, chemical synthesis of some novel pyrrolyl benzamide derivatives and evaluation of their inhibitory activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
    Joshi SD; Dixit SR; Basha J; Kulkarni VH; Aminabhavi TM; Nadagouda MN; Lherbet C
    Bioorg Chem; 2018 Dec; 81():440-453. PubMed ID: 30223149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.